Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Pacific Biosciences ( (PACB) ) has provided an update.
On January 12, 2026, PacBio reported preliminary unaudited results indicating that fourth-quarter 2025 revenue rose 14% year-on-year to approximately $44.6 million, while full-year 2025 revenue grew 4% to about $160.0 million, driven by strong uptake of its Revio and Vega sequencing systems and record consumables sales. The company also highlighted a sharp ramp in Vega placements, stable Revio pull-through, and a reduction in cash, cash equivalents, and investments to roughly $279.5 million from $389.9 million a year earlier, underscoring both growing traction in clinical sequencing applications and ongoing cash burn; management indicated that full audited 2025 results, which could differ materially from these preliminary figures, will be detailed when PacBio reports earnings in February and files its annual report.
The most recent analyst rating on (PACB) stock is a Buy with a $3.00 price target. To see the full list of analyst forecasts on Pacific Biosciences stock, see the PACB Stock Forecast page.
Spark’s Take on PACB Stock
According to Spark, TipRanks’ AI Analyst, PACB is a Neutral.
Pacific Biosciences’ stock score is primarily impacted by its poor financial performance, characterized by declining revenues and high leverage. Despite positive technical indicators suggesting bullish momentum, the negative valuation metrics due to ongoing losses weigh heavily on the overall score. The earnings call provided a mixed outlook, with some positive developments in consumable revenue and gross margins, but these were not enough to offset the financial challenges.
To see Spark’s full report on PACB stock, click here.
More about Pacific Biosciences
PacBio (Pacific Biosciences; NASDAQ: PACB) is a premier life science technology company that designs, develops, and manufactures advanced, high-accuracy sequencing solutions, including its HiFi long-read sequencing platforms. Its products support a broad range of research and clinical research applications in human germline sequencing, plant and animal sciences, infectious disease and microbiology, oncology, and other emerging genomic fields, with all systems currently marketed for research use only.
Average Trading Volume: 8,947,549
Technical Sentiment Signal: Buy
Current Market Cap: $615.9M
Learn more about PACB stock on TipRanks’ Stock Analysis page.